For General Information, page-1937

re: Could we pass Go and simply run a combination study?

Trying to parse these posts through a headache, so apologies if it's massively off the rails...

Are you/others suggesting that it's possible that the delay in analysis from the combination study could be due to it setting something larger in motion (e.g. meeting Big Pharma's funding requirements)?

So hypothetically, BP-x looked at the combo study results and were interested, but needed more to justify investment in a North American combo trial to their shareholders?

e.g. They may have wanted to see the toxicity study underway (tick) and a significant increase in dystrophin levels (or something) in the analysis we're waiting on?

That seems plausible to me. I find it hard to believe that the initial combo results went totally unnoticed.

On another note, I topped up for the first time in a while on Friday. The 50k order at 9.3c (executed at 9.2c) on open was me That might have been the COVID brain fog buying hahaha

Good luck!!